# Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib

> **NCT01487265** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 37 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** BKM120 and Erlotinib

## Key facts

- **NCT ID:** NCT01487265
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2016-05-31
- **Final completion:** 2017-12-11
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2019-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01487265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01487265, "Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01487265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*